Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STIM1 | Q13586 | 1/20 | 0.44 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.44 |
| ▸ | ORAI2 | Q96SN7 | 1/20 | 0.44 |
| ▸ | IL2 | P60568 | 4/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | P2RX7 | Q99572 | 6/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.39 |
| ▸ | RORC | P51449 | 4/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7916875 | 0.94 | IL2 (0.42) | STIM1ORAI1ORAI2IL2RORC | |
| Hydrochloric Acid SCHEMBL1782663 | 0.93 | IL2 (0.42) | STIM1ORAI1ORAI2IL2MEN1 | |
| SCHEMBL1783464 | 0.92 | STIM1 (0.47) | STIM1ORAI1ORAI2IL2P2RX7 | |
| SCHEMBL3830406 | 0.88 | STIM1 (0.44) | STIM1ORAI1ORAI2IL2L3MBTL1 | |
| SCHEMBL7913649 | 0.87 | SMN1; SMN2 (0.37) | STIM1ORAI1ORAI2IL2P2RX7 | |
| Hydrochloric Acid SCHEMBL1782512 | 0.86 | SMN1; SMN2 (0.36) | STIM1ORAI1ORAI2IL2P2RX7 | |
| SCHEMBL7922380 | 0.84 | IL2 (0.42) | STIM1ORAI1ORAI2IL2P2RX7 | |
| Hydrochloric Acid SCHEMBL1782891 | 0.84 | IL2 (0.42) | STIM1ORAI1ORAI2IL2P2RX7 | |
| SCHEMBL7920820 | 0.82 | STIM1 (0.44) | STIM1ORAI1ORAI2IL2L3MBTL1 | |
| SCHEMBL3824488 | 0.82 | IL2 (0.42) | STIM1ORAI1ORAI2IL2L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP (US) | 2013-11-14 | — | — | US | disclosed |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2012-07-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2011-05-19 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. | 2010-05-20 | — | — | US | disclosed |
| WO-2010039236-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | SYNTA PHARMACEUTICALS CORP. (US) | 2010-04-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303542-A1 | SUBSTITUTED PYRAZINAMIDE COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | NLRP3, NLRP1, CXCL8 | STIM1 1974/4885ORAI1 1558/4885ORAI2 1575/4885 |
| US-20100125080-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | STIM1 924/4885ORAI1 729/4885ORAI2 1267/4885 |
| US-20120183579-A1 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | STIM1 924/4885ORAI1 729/4885ORAI2 1267/4885 |
| US-20110118281-A9 | COMPOUNDS FOR INFLAMMATION AND IMMUNE-RELATED USES | CXCL8, CCR1, CCR8 | STIM1 924/4885ORAI1 729/4885ORAI2 1267/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.